Dr. Reddy's Laboratories Limited (RDY)
NYSE: RDY · Real-Time Price · USD
13.35
-0.09 (-0.67%)
Feb 21, 2025, 4:00 PM EST - Market closed
Dr. Reddy's Laboratories Revenue
Dr. Reddy's Laboratories had revenue of 83.59B INR in the quarter ending December 31, 2024, with 15.85% growth. This brings the company's revenue in the last twelve months to 311.31B, up 14.74% year-over-year. In the fiscal year ending March 31, 2024, Dr. Reddy's Laboratories had annual revenue of 279.16B with 13.54% growth.
Revenue (ttm)
311.31B INR
Revenue Growth
+14.74%
P/S Ratio
3.05
Revenue / Employee
11,509,354 INR
Employees
27,048
Market Cap
11.08B USD
Revenue Chart
* This company reports financials in INR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 279.16B | 33.29B | 13.54% |
| Mar 31, 2023 | 245.88B | 31.49B | 14.69% |
| Mar 31, 2022 | 214.39B | 24.67B | 13.00% |
| Mar 31, 2021 | 189.72B | 15.12B | 8.66% |
| Mar 31, 2020 | 174.60B | 20.75B | 13.49% |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
| Mar 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
RDY News
- 16 days ago - Dr. Reddy's enters into collaboration with Henlius for commercialization of HLX15 (daratumumab), a biosimilar candidate to Darzalex® & Darzalex Faspro® in the U.S., and Europe - Business Wire
- 17 days ago - Henlius and Dr. Reddy's Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S. - PRNewsWire
- 24 days ago - Dr. Reddy's Lab: Near-Term Worries And Underappreciated Potential Could Lead To Huge Returns - Seeking Alpha
- 4 weeks ago - Dr. Reddy's Laboratories Limited (RDY) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Dr. Reddy's Q3 & 9MFY25 Financial Results - Business Wire
- 3 months ago - Dr. Reddy's launches Toripalimab in India, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma - Business Wire
- 3 months ago - Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch of Ivermectin Tablets USP, 3 mg in US Market - Business Wire
- 3 months ago - Dr. Reddy's Laboratories Limited (RDY) Q2 2025 Earnings Call Transcript - Seeking Alpha